source
- Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipelineOberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…
- Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trialKailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…